What's new? Log in Free sign up

GSK (GSK)

Company Profile

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

Company profile

Ticker

GSK, GLAXF

Exchange

Website

CEO

Emma Walmsley

Incorporated

Location

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies ...

Former names

GLAXOSMITHKLINE PLC

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

GSK stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

Positive Phase III Ruby Results for Jemperli

Publication of 2023 Agm Notice

Statement: Zantac (Ranitidine) Litigation

Director/pdmr Shareholding

Director/pdmr Shareholding

Notice of effectiveness

Positive Phase III Results for Menabcwy Vaccine

Nucala Nda Accepted for Review In China

Director/pdmr Shareholding

Prospectus update (post-effective amendment)

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Wave Life Sciences Ltd.

Wave Life Sciences Ltd.

23andMe Holding Co.

Spero Therapeutics, Inc.

Spero Therapeutics, Inc.

Spero Therapeutics, Inc.

23andMe Holding Co.

23andMe Holding Co.

Financial summary

Financial statements Chart GSK financial data

Quarter (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from GSK earnings reports.

Institutional ownership, Q4 2022

GSK institutional ownership history Ownership history

13.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	775	683	+13.5%
Opened positions	182	166	+9.6%
Closed positions	90	305	-70.5%
Increased positions	217	95	+128.4%
Reduced positions	250	415	-39.8%

13F shares	Current	Prev Q	Change
Total value	9.68 tn	7.53 bn	+128404.3%
Total shares	275.98 mm	255.62 mm	+8.0%
Total puts	3.17 mm	5.91 mm	-46.4%
Total calls	6.73 mm	8.57 mm	-21.5%
Total put/call ratio	0.5	0.7	-31.7%

Largest owners	Shares	Value	Change
Dodge & Cox	64.93 mm	$2.28 tn	+10.8%
JTC Employer Solutions Trusteee	17.97 mm	$629.67 bn	+281.8%
FMR	14.96 mm	$525.71 bn	+6.3%
Arrowstreet Capital, Limited Partnership	14.04 mm	$492.06 bn	+74.6%
Fisher Asset Management	12.72 mm	$445.68 bn	+4.5%
T. Rowe Price	11.62 mm	$407.10 bn	+3.9%
GS Goldman Sachs	9.71 mm	$341.26 bn	+20.5%
STT State Street	7.42 mm	$263.17 bn	NEW
Acadian Asset Management	6.56 mm	$229.68 bn	+0.7%
Point72 Asset Management	6.47 mm	$227.42 bn	+40.0%

Largest transactions	Shares	Bought/sold	Change
JTC Employer Solutions Trusteee	17.97 mm	+13.26 mm	+281.8%
Capital International Investors	0.00	-11.07 mm	EXIT
STT State Street	7.42 mm	+7.42 mm	NEW
Two Sigma Investments	557.99 k	-6.58 mm	-92.2%
Dodge & Cox	64.93 mm	+6.35 mm	+10.8%
Arrowstreet Capital, Limited Partnership	14.04 mm	+6.00 mm	+74.6%
Primecap Management	3.77 mm	+3.32 mm	+753.7%
Renaissance Technologies	6.34 mm	-3.02 mm	-32.3%
Citadel Advisors	933.48 k	-2.78 mm	-74.9%
Two Sigma Advisers	2.19 mm	-2.32 mm	-51.4%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

GSK insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Sep 22	GSK	Ordinary Shares	Other	Dispose J	Yes	No	9.75	9,644,807	94.04 mm	0

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

GSK Unveils Detailed Phase 3 Data For Jemperli In Frontline Endometrial Cancer Patients

Reported Late Monday March 27, AnaptysBio And GSK Partnered Immuno-Oncology Agent Jemperli Plus Chemotherapy Demonstrates Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival For The Treatment Of Primary Advanced Or Recurrent Endometrial Cancer Versus Chemotherapy Alone In Phase 3 Ruby Trial

Results published in The New England Journal of Medicine and presented simultaneously at ESMO Virtual Plenary and SGO Annual Meeting

This Is What Whales Are Betting On GSK

Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information

Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories

Press releases

From Benzinga Pro

Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab-gxly) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone

72% and 36% reduction in the risk of disease progression or death observed in the dMMR/MSI-H population and overall patient population, respectivelyClinically meaningful overall survival trend observed at interim

GSK and Earvin "Magic" Johnson Partner to Raise Awareness of Risk of RSV in Older Adults

GSK launches national health education campaign, Sideline RSV, to highlight risk of Respiratory Syncytial Virus (RSV). Adults at highest risk for severe RSV infection include older adults and adults with chronic

Global Market for Acute Myeloid Leukemia Expected to Reach $3.2 Billion By 2029

FinancialNewsMedia.com News Commentary PALM BEACH, Fla., Feb. 22, 2023 /PRNewswire/ -- Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children. Leukemia is a type of

US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer

Nutriband Inc. to Present at the 2023 Transdermal and Microneedle Conference

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.